WallStreetZenWallStreetZen

NASDAQ: NVCT
Nuvectis Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NVCT stock forecasts and price targets.

Forecast return on equity

Is NVCT forecast to generate an efficient return?

Company
-201.22%
Industry
29.08%
Market
150.57%
NVCT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NVCT forecast to generate an efficient return on assets?

Company
-112.66%
Industry
-0.66%
NVCT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NVCT earnings per share forecast

What is NVCT's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.27
Avg 2 year Forecast
-$1.33
Avg 3 year Forecast
-$1.08

NVCT revenue forecast

What is NVCT's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$4.5M

NVCT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NVCT$9.71N/AN/A
CGEN$2.72$5.00+83.82%Strong Buy
IKT$1.93$5.00+159.07%Strong Buy
HELP$5.22$49.00+838.70%Strong Buy
ALXO$1.93$4.33+124.51%Strong Buy
View Top Biotech Stocks

Nuvectis Pharma Stock Forecast FAQ

What is NVCT's earnings growth forecast for 2026-2028?

(NASDAQ: NVCT) Nuvectis Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 21.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 67.82%.

Nuvectis Pharma's earnings in 2026 is -$29,589,000.On average, 6 Wall Street analysts forecast NVCT's earnings for 2026 to be -$33,753,741, with the lowest NVCT earnings forecast at -$35,093,280, and the highest NVCT earnings forecast at -$33,422,172. On average, 6 Wall Street analysts forecast NVCT's earnings for 2027 to be -$35,241,823, with the lowest NVCT earnings forecast at -$36,393,031, and the highest NVCT earnings forecast at -$32,308,099.

In 2028, NVCT is forecast to generate -$28,613,092 in earnings, with the lowest earnings forecast at -$54,849,497 and the highest earnings forecast at $38,435,497.

If you're new to stock investing, here's how to buy Nuvectis Pharma stock.

What is NVCT's revenue growth forecast for 2026-2028?

(NASDAQ: NVCT) Nuvectis Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.72%.

Nuvectis Pharma's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast NVCT's revenue for 2026 to be $0, with the lowest NVCT revenue forecast at $0, and the highest NVCT revenue forecast at $0. On average, 6 Wall Street analysts forecast NVCT's revenue for 2027 to be $0, with the lowest NVCT revenue forecast at $0, and the highest NVCT revenue forecast at $0.

In 2028, NVCT is forecast to generate $118,754,811 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $319,367,417.

What is NVCT's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: NVCT) forecast ROA is -112.66%, which is lower than the forecast US Biotechnology industry average of -0.66%.

What is NVCT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NVCT) Nuvectis Pharma's current Earnings Per Share (EPS) is -$1.31. On average, analysts forecast that NVCT's EPS will be -$1.27 for 2026, with the lowest EPS forecast at -$1.32, and the highest EPS forecast at -$1.26. On average, analysts forecast that NVCT's EPS will be -$1.33 for 2027, with the lowest EPS forecast at -$1.37, and the highest EPS forecast at -$1.22. In 2028, NVCT's EPS is forecast to hit -$1.08 (min: -$2.07, max: $1.45).

What is NVCT's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: NVCT) forecast ROE is -201.22%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.